Loading company…
Pheno Therapeutics develops neuroprotective therapies targeting the GPR17 receptor for multiple sclerosis and other disorders.
Pheno Therapeutics develops neuroprotective treatments that target the GPR17 receptor, including potential therapies for multiple sclerosis and other conditions involving neuronal damage. The company is based in Edinburgh, UK. It raised GBP 5 million in a Series A round on March 28, 2019, with investment from Advent Life Sciences, LifeArc, and Scottish Investment Bank. Fraser Murray is CEO; Neil Carragher and Siddharthan Chandran are founders.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in